Experimental cancer drug DS-9606a tested in early trial, but stopped early
NCT ID NCT05394675
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested an experimental drug called DS-9606a in 88 people with advanced solid tumors that have a specific protein (Claudin-6). The main goal was to check safety and find the right dose. The trial was terminated, meaning it stopped before completion, so we have limited information on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DS-9606a (an experimental antibody-drug conjugate given by IV infusion)
What this could lead to
If successful, this could point toward a new treatment option for certain advanced cancers that express Claudin-6.
What could go wrong
This is a very early Phase 1 trial that was terminated, so results are limited. The drug may not be effective or safe enough to continue development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Florida Cancer Specialists & Research Institute, LLC
Fort Myers, Florida, 33916, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
SCRI at HealthONE
Denver, Colorado, 80216, United States
-
Sarah Cannon Research Institute UK
London, W1G 6AD, United Kingdom
-
The Royal Marsden NHS Trust
Sutton, SM2 5PT, United Kingdom